阿托伐他汀强化治疗对ACS合并糖尿病患者介入术后C一反应蛋白影响.docVIP

阿托伐他汀强化治疗对ACS合并糖尿病患者介入术后C一反应蛋白影响 　　[摘要]目的：研究不同剂量阿托伐他汀对合并糖尿病的ACS患者经皮冠状动脉介入（PCI）治疗术后炎症因子、调脂疗效的影响。方法：对72例合并糖尿病的ACS患者行冠状动脉介入术，随机分为阿托伐他汀20mg组（A组）36例，40mg组（B组）38例，手术当天、术后24小时、术后2周、术后4周空腹采血，测定血清高敏C一反应蛋白（hs.CRP）以及血脂水平。结果：阿托伐他汀40mg组较20mg组PCI术后血清hs―CRP浓度降低更明显。2组术后2周血脂水平较术前略有降低，但无统计学意义，两组术后4周血脂水平较术前降低，阿托伐他汀40mg组较20mg组PCI术后血清低密度脂蛋白（LDL-C）浓度降低更明显。结论：冠脉介入术后患者血清hs-CRP升高；阿托伐他汀能降低冠脉介入术后患者血清hs-CRP，LDL―C水平40mg阿托伐他汀治疗较20mg阿托伐他汀疗效更好。 　　[关键词]糖尿病；ACS；阿托伐他汀；经皮冠状动脉介入术；c反应蛋白 　　[Abstract]Objective: study the different doses for Atorvastatin patients with diabetes to merge the ACS percutaneous coronary intervention (PCI) treatment of postoperative inflammatory factor, and lipid curative effect. Method: do intraoperative coronary intervention for 72 cases of patients with diabetes mellitus ACS, randomized intraoperative atorvastatin 20mg group (group A) (36 cases) and 40mg group (group B) 38 cases, surgery and postoperative day 24 hours, after two weeks, postoperative 4 weeks, determine fasting blood serum gao min C-reactive protein (CRP) and hs. Lipid leels. Results: 40mg atorvastatin 20mg group after group a PCI serum hs CRP were reduced more significantly. Group 2 after two weeks of preoperative reduced slightly lower than lipid levels, but this was not statistically significant, two groups of postoperative 4 weeks lipid levels were improved reduced, atorvastatin group with 40mg after group a PCI serum low-density lipoprotein (LDL) - C) concentration was apparent lower than the 20mg group. Conclusion: the serum hs-CRP for coronary intervention postoperative patients was elevated; Atorvastatin reduced serum hs-CRP, LDL―C level 40mg Atorvastatin treatment is better than 20mg. 　　[Keywords]Diabetes; The ACS; Atorvastatin; Percutaneous coronary intervention; C-reactiveprotein (CRP) 　　 　　炎症过程在动脉粥样硬化及其并发症的发生发展过程中起着重要作用或枢纽作用，是冠状动脉不稳定斑块破裂、出血、血栓形成发生急性冠状动脉综合征（ACS）的主要始动机制同时，越来越多的证据表明，炎性因子在糖尿病冠状动脉粥样硬化发病中起重要作用。高敏C-反应蛋白（hs―CRP）是炎症的一种敏感性指标，国内外研究结果表明，ACS患者血清C一反应蛋白水平明显升高，且升高程度与随后发生的心血管事件明显相关。研究证明ACS患者介